title: Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
abstract: Aberrant proangiogenic pathways have long been implicated in tumorigenesis and metastasis. Antiangiogenic therapies have shown efficacy in the treatment of a variety of solid tumors including lung, breast, colon, glioblastomas, and other solid tumor types. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), is an orally bioavailable agent currently being studied in multiple tumor types. Apatinib has shown a survival benefit in gastric cancer in a phase III trial and non-small cell lung cancer in a phase II trial. With a favorable side effect profile and improved outcomes, apatinib has demonstrated a substantial potential to augment therapeutic options in a variety of tumor types.
authors.affiliation: Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Scott
authors.affiliation: Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.
authors.forename: W A
authors.initials: WA
authors.lastname: Messersmith
authors.affiliation: Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA. Antonio.Jimeno@UCDenver.edu.
authors.forename: A
authors.initials: A
authors.lastname: Jimeno
mesh_terms: D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D011725:Pyridines; C553458:apatinib; C000588866:KDR protein, human; D040301:Vascular Endothelial Growth Factor Receptor-2
keywords: Antiangiogenic drugs; Apatinib; Solid tumor; VEGF; VEGFR-2